Patent EP0514720A2 successfully refreshed from Google Patents.
EP0514720A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Bone growth factors and inhibitors of bone resorption for promoting bone formation
Assignee: Celtrix Pharmaceuticals Inc
•
Filing: 1992-05-08
•
Granted: —
•
Expires: 2012-05-08
Abstract
Abstract Bone growth factors are used to stimulate new bone formation when administered with agents that inhibit bone resorption. These therapeutic combinations result in an enhanced rate of bone formation with an increase in bone mass.
Inventors
- 👤 Steven W. Adams
- 👤 Rosa Armstrong
- 👤 David Rosen
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 17:50
CPC Classifications
A; A61; A61K; A61K45/00; A61K45/06; A61K31/00; A61K31/13; A61K31/135; A61K31/138; A61K31/56; A61K31/565; A61K31/66; A61K31/662; A61K31/663; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61K38/22; A61K38/23; A61P; A61P19/00; A61P19/08; A61P19/10; A61P3/00; A61P3/02; A61P35/00; A61P43/00
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
19 words
A pharmaceutical composition comprising a bone growth factor and an inhibitor of bone resorption in a pharmaceutically acceptable excipient.
Claim 2
Dependent Claim
13 words
A composition according to claim 1, wherein the bone growth factor is TGF-β.
Claim 3
Dependent Claim
14 words
A composition according to claim 1, wherein the bone growth factor is an activin.
Claim 4
Dependent Claim
17 words
A composition according to claim 1, wherein the bone growth factor is a bone morphogenic protein (BMP).
Claim 5
Dependent Claim
14 words
A composition according to claim 1, wherein the bone growth factor is an IGF.
Claim 6
Dependent Claim
15 words
A composition according to claim 1, wherein the bone growth factor is parathyroid hormone (PTH).
Claim 7
Dependent Claim
20 words
A composition according to any one of claims 1 to 6, wherein the inhibitor of bone resorption is an estrogen.
Claim 8
Dependent Claim
20 words
A composition according to any one of claims 1 to 6, wherein the inhibitor of bone resorption is a calcitonin.
Claim 9
Dependent Claim
20 words
A composition according to any one of claims 1 to 6, wherein the inhibitor of bone resorption is a bisphosphonate.
Claim 10
Dependent Claim
20 words
A composition according to any one of claims 1 to 6, wherein the inhibitor of bone resorption is sodium fluoride.
Claim 11
Dependent Claim
20 words
A composition according to any one of claims 1 to 6, wherein the inhibitor of bone resorption is a tamoxifen.
Claim 12
Dependent Claim
27 words
A composition according to any one of the preceding claims, wherein the molar ratio of bone growth protein to inhibitor of bone resorption is 10:1 to 1:10.
Claim 13
Dependent Claim
23 words
A composition according to claim 12, wherein the molar ratio of bone growth protein to inhibitor of bone resorption is 5:1 to 1:1.
Claim 14
Dependent Claim
23 words
A composition according to any one of the preceding claims wherein the bone growth protein is conjugated to the inhibitor of bone resorption.
Claim 15
Dependent Claim
15 words
A composition according to any one of the preceding claims, further comprising a sustained-release vehicle.
Claim 16
Dependent Claim
29 words
A composition as defined in any one of claims 1 o 15 for use in a method of treatment of a human or animal subject for inducing bone formation.
Claim 17
Dependent Claim
29 words
A composition as defined in any one of claims 1 to 15 for use in a method of treatment of a human or animal subject for treating bone loss.
Claim 18
Dependent Claim
22 words
A composition according to claim 16 or 17 wherein the bone growth factor and the inhibitor of bone resorption are administered sequentially.
Claim 19
Dependent Claim
22 words
A composition according to claim 16 or 17 wherein the bone growth factor and the inhibitor of bone resorption are administered simultaneously.
Claim 20
Dependent Claim
48 words
A composition according to any one of claims 16 to 19 wherein the bone loss is osteoporosis-related, or osteohalisteresis-related or age related or is related to steroid therapy or is osteoarthritis-related or is related to Paget's disease or to cancer eg. multiple myeloma or wherein treatment is prophylactic.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.